INTRODUCTION
============

Modern neuroimaging is critical to the clinical management of patients with brain tumor. Noninvasive neuroimaging techniques now offer the opportunity to incorporate functional, hemodynamic, metabolic, cellular, microstructural, and genetic information into the assessment of brain tumor patients \[[@B1],[@B2],[@B3]\]. These imaging tools are being applied to diagnose and grade brain tumors preoperatively, to plan and navigate surgery intra-operatively, to monitor and assess treatment response and patient prognosis, and to understand the effects of treatment on the patients brain. Ongoing research in brain tumor imaging attempts to develop, validate, and clinically implement advanced neuroimaging techniques that can aid in the diagnosis and identification of any disease factors or clinically relevant risk factors specific to each patient, the selection and implementation of the appropriate treatment targeting the unique biology of the individual tumor, and the detection of early treatment failure and any early or late onset therapy related complications.

This article provides an overview of the current state-of-the art clinical brain tumor imaging in 2015. We will discuss general magnetic resonance (MR) imaging methods and their application to the diagnosis of, treatment planning and navigation, and disease monitoring in patients with brain tumor. We will review the strengths, limitations, and pitfalls of diffusion-weighted imaging (DWI) techniques, MR spectroscopy (MRS), perfusion imaging, positron emission tomography (PET)/MR, and functional imaging. A detailed discussion of the underlying MR physics is beyond the scope of this clinical review and will only be mentioned briefly when relevant. We intend to discuss the modern clinical application of these methods in the daily evaluation and treatment of patients with brain tumor.

BRAIN TUMOR BIOLOGY AND GENETICS
================================

The World Health Organization (WHO) defines four grades of brain tumors based primarily upon tumor aggressiveness with grade I tumors being relatively non-aggressive and grade IV tumors being very aggressive \[[@B4]\]. Traditionally with the first edition in 1979, WHO grades were assigned on the basis of histologic features such as mitotic activity, necrosis, and infiltration \[[@B5]\]. The second edition, in 1993, incorporated immunohistochemistry, and the third edition in 2000 incorporated genetic profiles into the definitions of brain tumors \[[@B6],[@B7]\]. The most recent WHO central nervous system (CNS) tumor classification system was published in 2007 and continues to integrate genetic profiles into tumor definitions and histological variants \[[@B4]\]. Genetics and molecular profiles of brain tumors continue to be an active area of research with diagnostic, prognostic, therapeutic, and imaging implications \[[@B2],[@B8],[@B9]\]. Here we review the main relevant molecular and genetic aberrations in brain tumors that are relevant to understanding individual variations in tumor biology, response to therapy, and prognosis. An overview is provided in [Table 1](#T1){ref-type="table"}.

TP53
----

The p53 tumor suppression pathway is commonly abnormal in high-grade gliomas. The p53 gene (*TP53*) has been reported to be mutated in approximately 30-40% and the overall pathway has been reported to be disrupted in more than 80% of tumors \[[@B2],[@B9],[@B10],[@B11]\]. The p53 protein is involved in DNA repair, arresting the cell cycle for DNA repair when there is DNA damage, and in initiating apoptosis. Abnormalities in the p53 tumor suppression pathway can lead to genetic instability, reduced apoptosis, and angiogenesis. The p53 tumor suppression pathway may be disrupted by mutation or deletion of the *TP53* gene or by overexpression of inhibitors of p53 including murine double minute 2 which may result by direct mutation or by mutation of cyclin-dependent kinase inhibitor 2A (*CDKN2A*) \[[@B2],[@B9],[@B11]\].

RB1
---

The retinoblastoma 1 (*RB1*) tumor suppression pathway is commonly abnormal in glioblastoma, and is disrupted in more than 75% of tumors \[[@B2],[@B9]\]. Rb1 is a protein that blocks cell cycle progression and if the pathway is abnormal there may be unchecked cell cycle progression \[[@B2]\]. The Rb1 tumor suppression pathway may be disrupted by a direct mutation of the *RB1* gene or by overexpression of cyclin-dependent kinase 4 (*CDK4*). Overexpression of *CDK4* may result from amplification or more commonly through deletion of an inhibitor of *CDK4*, *CDKN2A* \[[@B2],[@B9],[@B11]\].

EGFR and PTEN
-------------

The epidermal growth factor receptor (EGFR) is a trans-membrane receptor in the receptor tyrosine kinase (RTK), phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K) cell proliferation pathway \[[@B2]\]. *EGFRvIII*, a mutated form of EGFR, plays a prominent role in tumorigenesis of glioblastoma, but the underlying mechanisms have remained elusive. *EGFRvIII* amplification can lead to increased downstream activity resulting in proangiogenic signaling, increased proliferation, increased tumor cell survival, and migration \[[@B2]\]. *EGFRvIII* amplifications have been reported in approximately 40% of primary glioblastomas \[[@B4],[@B8],[@B12]\]. *EGFRvIII* amplification has been reported to be a predictor of poor survival, however, other studies have failed to show this effect \[[@B4],[@B8],[@B13],[@B14]\]. Studies have reported that *EGFRvIII* amplification can predict response to tyrosine kinase inhibitors, especially when *PTEN* expression is preserved \[[@B15]\].

*PTEN* is a tumor suppressor gene expressing a protein involved in the same RTK/PTEN/PI3K cell proliferation pathway as *EGFR* \[[@B2]\]. *PTEN* mutations are estimated to occur in 15-40% of primary glioblastomas but up to 80% of glioblastomas have loss of chromosome 10q in the region where *PTEN* is located (10q23) \[[@B8],[@B16]\]. Chromosome 10q loss, *PTEN* mutations, and *EGFR* amplification are frequently seen together in the small cell phenotype of glioblastoma \[[@B4],[@B8]\]. *PTEN* deletions have been reported to be a poor prognostic factor for pediatric glioblastomas, however, this has not been found true in adult patients \[[@B8],[@B17]\].

Several magnetic resonance imaging (MRI) parameters have been reported as predictive of *EGFR* amplification. A high ratio of contrast enhancing tissue to necrotic tissue (≥1), lower apparent diffusion coefficient (ADC) values, increased T2 to contrast enhancing volume, and deceased T2 border sharpness have all been described with *EGFR* amplification \[[@B2],[@B18],[@B19],[@B20]\]. In addition, increased normalized tumor blood volume has been reported in tumors with *EGFR* amplification, *PTEN* deletion, and normal unmethylated O^6^-methylguanine-DNA methyl-transferase (*MGMT*) \[[@B21]\].

IDH1/IDH2
---------

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are enzymes involved in the citric acid cycle. *IDH1* gene mutations are seen in about 5% of patients with primary glioblastoma but are seen in 70-80% of grade II-III gliomas and secondary glioblastomas (glioblastomas arising from low grade gliomas) \[[@B2],[@B8],[@B22],[@B23],[@B24]\]. IDH2 mutations are mostly seen in oligodendroglial tumors \[[@B8],[@B24]\]. Patients with *IDH1/2* mutations have been reported to have better survival independent of therapy \[[@B23],[@B24],[@B25],[@B26]\]. On imaging *IDH1* mutated tumors are reported to be more likely to be multi-focal, invasive, and have minimal or no contrast enhancement \[[@B2],[@B27],[@B28]\]. The mutant IDH1 and 2 enzymes have shown neomorphic enzymatic capacity to covert alpha-ketoglutarate into 2-hydroxy-glutarate (2-HG), a small oncometabolite. Detection and semi-quantitation of 2-HG by proton MRS has been reported and this noninvasive detection of 2-HG oncometabolite may prove to be a valuable diagnostic and prognostic biomarker \[[@B29]\].

1p/19q
------

Co-deletion of chromosomes 1p and 19q results from an unbalanced centromeric translocation and is considered indicative of oligodendroglial lineage \[[@B8]\]. 1p/19q co-deletion is seen in approximately 80% of oligodendrogliomas, 60% of anaplastic oligodendrogliomas, 30-50% of oligoastrocytomas, and 20-30% of anaplastic oligoastrocytomas and is frequently seen with *IDH1/2* mutations \[[@B8],[@B30],[@B31]\]. 1p/19q co-deletion has been reported as a favorable prognostic factor and to indicate patients who would benefit from chemoradiation although this significance may be complicated by the frequency of favorable *IDH1/2* mutations and unfavorable additional chromosomal mutations \[[@B26],[@B32],[@B33],[@B34],[@B35],[@B36]\]. This prognostic significance likely depends on the type of 1p loss, with partial 1p losses being associated with poorer survival than complete 1p losses \[[@B37]\]. 1p/19q co-deleted tumors have been reported to be more likely to have indistinct/irregular margins and more heterogeneous T1 and T2 signal characteristics than tumors of the same histology but with 1p/19q intact although the differences were modest and subjective \[[@B38]\]. Elevated perfusion has also been suggested in low-grade oligodendrogliomas with 1p/19q loss although in small studies \[[@B39],[@B40]\].

MGMT
----

*MGMT* is a DNA repair protein involved in repairing damage induced by alkylating agents \[[@B8],[@B36]\]. Methylation of the *MGMT* gene promoter reduces binding of transcription factors and decreases gene expression \[[@B41]\]. Methylation thus theoretically increases sensitivity to alkylating chemotherapeutics \[[@B42]\]. *MGMT* promoter methylation is reported to be present in 35-75% of glioblastomas \[[@B8],[@B42]\]. Multiple studies have shown a better prognosis and response for glioblastoma patients with *MGMT* promoter methylation receiving temozolamide \[[@B42],[@B43],[@B44],[@B45]\]. Pseudo-progression after radiation and chemotherapy is more common in tumors with *MGMT* promoter methylation and *MGMT* promoter methylation should be this taken into account when interpreting follow-up MRIs \[[@B46],[@B47]\].

BRAF
----

*BRAF* is a proto-oncogene that encodes the protein B-Raf, which is involved in the mitogen-activated protein kinase pathway \[[@B8],[@B48]\]. This pathway is involved in cell proliferation, differentiation, survival, and apoptosis. Activating *BRAF* mutations are seen in numerous malignancies, most frequently however in melanoma \[[@B49]\]. Pilocytic astrocytomas have been shown to have *BRAF* mutations with a specific duplication/fusion mutation occurring in 65-80% of pilocytic astrocytomas \[[@B50],[@B51]\]. A separate specific point mutation (V600E) is seen in up to 80% of pleomorphic xanthoastrocytomas and 25% of gangliogliomas \[[@B8],[@B52]\].

ATRX
----

The alpha thalassemia-mental retardation syndrome X-linked (*ATRX*) gene encodes a protein that is involved in telomere maintenance in a mechanism that does not involve telomerases known as alternative lengthening of telomeres \[[@B36],[@B53],[@B54]\]. *ATRX* mutations have been reported in tumors of astrocytic lineage \[[@B55],[@B56]\]. *ATRX* mutations are associated with *TP53* and *IDH1* mutations and are generally not seen with 1p/19q co-deletions and are thus useful in distinguishing from tumors of oligodendroglial origin \[[@B55],[@B56],[@B57],[@B58]\]. *ATRX* loss has been reported as a favorable prognostic indicator in patients whose tumors also had *IDH1* mutations \[[@B59]\].

Histone H3
----------

Histones are proteins involved in the packaging of DNA. Recently, mutations have been identified in the gene encoding histone 3 (*H3F3A*) in pediatric patients with glioblastomas and pontine gliomas \[[@B36],[@B58],[@B60]\]. These mutations have been reported at distinct locations in the histone variants H3.1 and H3.3, one involving a Lysine (Lys27) in H3.1 and H3.3 and one involving a glycine in H3.3 (Gly34) \[[@B58],[@B60],[@B61]\]. The *H3F3A* Lys27 mutation is reported to have a particularly poor prognosis \[[@B57]\]. These mutations are generally not seen together with *IDH1* mutations and thus represent an alternative group of tumors with distinct molecular aberrations \[[@B61]\].

STRUCTURAL AND HIGH RESOLUTION IMAGING
======================================

Computed tomography (CT) may be the first modality employed in a patient presenting with a brain tumor but for the most part MRI is the primary imaging modality in brain tumor patients. The role of CT is largely relegated to emergent imaging in the detection of hemorrhage, herniation, and hydrocephalus but mass effect from brain tumors and calcification within brain tumors such as oligodendrogliomas or menigiomas can potentially be detected ([Fig. 1](#F1){ref-type="fig"}) \[[@B62],[@B63]\].

Structural MRI sequences play a major role in the evaluation of and treatment planning of brain tumors. Standard sequences performed utilizing spin-echo techniques include T2 fluid-attenuated inversion recovery (FLAIR), pre-gadolinium T1, and post-gadolinium T1. These sequences are preferably performed in at least 2-orthogonal planes or obtained with a 3-dimensional (3D) sequence that is reformatted into orthogonal planes (i.e., 3D-T2 FLAIR). High-resolution iso-volumetric sequences such as high-resolution 3D T2 sequences and post-gadolinium T1 spoiled gradient recalled acquisition (SPGR) or similar sequences are generally performed preoperatively with fiducials in place for use with intraoperative navigational software \[[@B64],[@B65]\]. Similarly, post-gadolinium T1 SPGR sequences are performed with a stereotactic head frame in place prior to stereotactic radiosurgery \[[@B66],[@B67]\]. High-resolution 3D T2^\*^ gradient echo sequences such as susceptibility weighted imaging (SWI) are also routinely performed. These susceptibility sensitive sequences are very sensitive to blood products and calcification and may be helpful to depict post-radiotherapy micro-hemorrhages \[[@B68],[@B69],[@B70]\].

The primary roles of structural MRI in initial brain tumor evaluation includes determining the location of the lesion (i.e., intra-axial vs. extra-axial), establishing the specific location within the brain for treatment/biopsy planning, evaluating mass effect on the brain, ventricular system, and vasculature, and along with physiologic MRI sequences suggesting a possible diagnosis. Extra-axial tumors such as meningiomas, schwannomas, and skull base tumors can generally but not always be differentiated from intra-axial tumors. The differential diagnosis for intra-axial tumors depends on patient age and the presence of another primary malignancy \[[@B71],[@B72]\].

Making a diagnosis of a specific tumor type can be challenging but often the correct diagnosis can be suggested in a short list of likely possibilities. Contrast-enhancement signifies local breakdown of the blood brain barrier and is a key feature seen in many brain tumors and other mass lesions ([Fig. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}). Within gliomas, contrast enhancement is generally considered to be associated with high-grade tumor ([Fig. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}) although certain low-grade gliomas such as pilocytic astrocytomas in children generally enhance and certain high-grade gliomas may not enhance \[[@B73],[@B74],[@B75],[@B76],[@B77]\]. Peri-tumoral edema is generally T2/FLAIR hyperintense signal abnormality surrounding the main mass lesion ([Fig. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). This may in some instances such as with me-tastasis ([Fig. 4](#F4){ref-type="fig"}) represent predominately vasogenic edema surrounding the lesion, however with gliomas the peri-tumoral edema generally also represents infiltrative edema with tumor cells infiltrating into the regions of non-enhancing T2/FLAIR signal abnormality \[[@B1],[@B78],[@B79],[@B80],[@B81]\]. The number of lesions is an important factor to consider as a large number of lesions may signify certain pathologies such as metastases; however, metastasis can be solitary, as can tumor mimics such as demyelinating lesions or cerebral abscesses \[[@B82],[@B83],[@B84],[@B85],[@B86],[@B87]\]. Other potentially distinguishing features to note include a cyst and mural nodule morphology (seen with the lower grade tumors hemangioblastoma, pilocytic astrocytoma, ganglioglioma, and pleomorphic xanthoastrocytoma), calcification ([Fig. 1](#F1){ref-type="fig"}) (generally seen with oligodendrogliomas), and necrosis and hemorrhage (generally seen in higher grade gliomas and hemorrhage also in certain metastases) \[[@B62],[@B88],[@B89],[@B90]\].

Many of the same features are important in the ongoing evaluation of patients with known brain tumors. Per the updated Response Assesment in Neuro-Oncology working group a complete response to therapy for high-grade gliomas is defined as complete resolution of contrast enhancing disease with stable or decreased T2/FLAIR signal abnormality while not on corticosteroids; a partial response is defined as no new lesions, a ≥50% reduction in contrast enhancing disease, and stable or decreased T2/FLAIR abnormality while on stable or decreased dose of corticosteroids; stable disease is defined as no new lesions, \<50% decrease but \<25% increase in contrast enhancing disease, and stable or decreased T2/FLAIR abnormality while on stable or decreased dose of corticosteroids; and progressive disease is defined as any new lesion, a ≥25% increase in contrast enhancing disease, or increased T2/FLAIR abnormality \[[@B91]\]. These assessment criteria provide a framework for evaluation but do not account for some of the subtleties and nuances of evaluation of the post-treatment brain. A pseudo-response may be seen with a marked decrease in contrast en-hancement following treatment with bevacizumab, an antian-giogenic agent uside in recurrent glioblastoma \[[@B91],[@B92],[@B93],[@B94]\]. On the other hand, pseudo-progression may be seen as an increase in the contrast enhancing tumor and T2/FLAIR signal abnormality. Pseudo-progression is often associated with radiotherapy and temozolamide where it is seen in around 20% of patients (approximately 1/2 of the patients who initially \"progress\" on imaging) and may be seen more frequently in tumors with *MGMT* promoter methylation \[[@B46],[@B47],[@B91],[@B95],[@B96]\]. Follow-up studies and physiologic MRI sequences may be useful in the evaluation of pseudo-response and pseudo-progression. T2^\*^ based susceptibility sequences such as SWI may show small micro-hemorrhages develop over time in patients who have received radiation therapy \[[@B70],[@B97],[@B98]\]. These small micro-hemorrhages likely indicate delayed toxicity of radiation on the microvasculature of the brain. An overview of imaging techniques and general major utility is presented in [Table 2](#T2){ref-type="table"}.

DIFFUSION-WEIGHTED IMAGING
==========================

DWI offers insight into the diffusion of water molecules in tissues and can be used to calculate the ADC. DWI is a routine sequence that has become indispensable in the evaluation of stroke but also offers value in the evaluation of brain tumors. ADC values derived from DWI have been shown to be decreas-ed in highly cellular tumors such as CNS lymphoma, medulloblastoma, and high-grade glioma and to be deceased in highly viscous materials such as that within cerebral abscesses \[[@B84],[@B85],[@B86],[@B87],[@B99],[@B100],[@B101],[@B102]\]. With regards to gliomas, lower ADC values have been reported in higher-grade gliomas than lower-grade gliomas and lower ADC values have been reported to have a poorer prognosis independent of tumor grade \[[@B103],[@B104],[@B105]\]. Similarly in primary CNS lymphoma lower ADC values have been reported to be associated with a poorer prognosis \[[@B99],[@B106]\]. ADC values have also been reported to be higher in the vasogenic peritumoral edema T2/FLAIR abnormality surrounding metastases than in the more cellular infiltrative peritumoral edema T2/FLAIR abnormality seen in glioblastoma although this has not been found consistently in all studies \[[@B105],[@B107],[@B108],[@B109]\].

In the immediate post-operative setting it is common to see small areas of reduced diffusion at the surgical bed indicating areas of devitalized tumor tissue or ischemic brain tissue during surgery \[[@B110]\]. These small areas of postoperative injury may be caused by a variety of reasons including direct surgical trauma, retraction, vascular injury, and devascularization. The clinical implication of this finding is in the knowledge that these areas may be expected to develop contrast enhancement and normalization of ADC on subsequent imaging as a cerebral infarction would be expected to and that the contrast enhancement should not be mistaken for tumor progression \[[@B110]\].

DWI and quantitative ADC measurements may also be helpful in the setting of pseudo-response and pseudo-progression. In pseudo-response to bevacizumab, DWI may be useful to demonstrate persistent or progressive tumor despite the lack of contrast enhancement caused by the antiangiogenic effects of bevacizumab \[[@B111]\]. Histogram analysis of ADC maps has also been used to demonstrate poorer survival in patients with recurrent glioblastoma being treated with bevacizumab \[[@B112]\]. In the setting of possible pseudo-progression DWI/ADC may potentially offer some utility. Lower ADC values have been reported in tumor progression than in pseudo-progression, presumably due to the cellular nature of true tumor and the edema associated with the inflammatory response in pseudo-pro-gression \[[@B113],[@B114]\].

Diffusion-tensor imaging (DTI) involves more directions of interrogation than standard DWI but provides additional parameters and abilities over DWI. DTI provides information on anisotropic diffusion characterized by eigenvectors (direction) and eigenvalues (magnitude), which can be used to derive numerous parameters. DTI and other similar advanced predominately research techniques such as diffusion-spectrum imaging, diffusion-kurtosis imaging, tract-density imaging, and numerous others provide additional insight beyond DWI into the microstructure and integrity of the white matter. Fractional anisotropy (FA), mean diffusivity, track density, neuronal density and multiple other measures derived from these techniques offer additional means to study brain tumors and the effects of treatment. DTI is currently most relevant clinically as DTI-tractography where white matter fiber tracts can be displayed three-dimensionally for navigational purposes ([Fig. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}) \[[@B65],[@B115]\]. Tractography of the corticospinal tract is routinely displayed superimposed on high-resolution 3D T2-weighted and post-gadolinium SPGR images for intraoperative navigational purposes in order to avoid injuring the corticospinal tracts. FA derived from DTI is a measure of the directional nature of water diffusivity and has been used as a marker of white matter integrity in multiple conditions. FA has been shown to decrease in normal appearing white matter following radiation therapy and thus offers insight into the effects of radiation damage to the brains of brain tumors patients \[[@B116],[@B117]\]. FA has also been reported to be increased in the infiltrative peritumoral edema surrounding high-grade gliomas as compared to the vasogenic edema surrounding metastases, presumably due to the more ordered nature of the more cellular edema associated with gliomas \[[@B79]\].

PERFUSION IMAGING
=================

The two main methods of MR perfusion imaging include T2^\*^-weighted dynamic susceptibility contrast-enhanced (DSC) perfusion and T1-weighted dynamic contrast-enhanced (DCE) perfusion. DSC is a first-pass bolus tracking blood volume technique and DCE is a steady state permeability technique. Both can be used to derive multiple perfusion parameters such as cerebral blood volume (CBV) and endothelial transfer coefficient (K^trans^). Arterial spin labeling is a non-contrast perfusion technique, which may prove useful in the future but has not yet been as well studied or established in the evaluation of brain tumors. The complexity of perfusion data sets, which consist of hemodynamic parameters calculated on a pixel-by-pixel basis, and the heterogeneity of brain tumors make reliable interpretation of these studies challenging.

Relative cerebral blood volume (rCBV), which is the calculated CBV relative to the contralateral side, is the most widely used parameter derived from DSC and is considered a marker of angiogenesis. rCBV may be helpful in distinguishing high-grade from low-grade gliomas as high-grade gliomas have been found to have higher rCBV than low-grade gliomas, however this should be used with caution as oligodendrogliomas can have high rCBVs \[[@B118],[@B119],[@B120],[@B121],[@B122]\]. Metastases can have high rCBV similar to high-grade gliomas however they tend to have very leaky capillaries in the tumors and as a result may demonstrate leakage of contrast in the bolus phase and as a result the signal intensity curve may not return to baseline ([Fig. 4](#F4){ref-type="fig"}) \[[@B1],[@B82]\]. A similar pattern resulting from highly leaky capillaries has been seen with choroid plexus tumors \[[@B1],[@B123]\]. rCBV has also been reported to more elevated in the infiltrate more cellular peritumoral T2/FLAIR abnormality surrounding high-grade gliomas as compared to the vasogenic peritumoral T2/FLAIR abnormality surrounding metastases \[[@B80]\]. DSC may also be useful in distinguishing tumefactive demyelinating lesions from high-grade gliomas as tumefactive demyelinating lesions generally have a lower rCBV \[[@B83]\]. DSC may also be helpful in the ongoing evaluation of patients with known brain tumors, as recurrent or residual tumor has been shown to have higher rCBV than pseudo-progression or radiation necrosis in the setting of gliomas and metastases \[[@B47],[@B124],[@B125]\].

The main metric derived from DCE perfusion MRI is K^trans^. considered a measure of microvascular permeability. DCE perfusion imaging is less frequently used than DSC but offers some theoretical advantages including better spatial resolution and less susceptibility artifact \[[@B1]\]. DCE may potentially be used to distinguish low-grade from high-grade gliomas with higher K^trans^ presumably due to greater capillary permeability seen in higher-grade gliomas \[[@B126],[@B127],[@B128],[@B129]\]. DCE has not been as extensively studied in the evaluation of treatment response as DSC but has been reported to be able to distinguish recurrent or progressive tumor from pseudo-progression using the maximum slope of initial enhancement \[[@B130]\]. DCE perfusion imaging offers potential advantage over DSC perfusion imaging due to its resilience to susceptibility artifact, higher spatial resolution, and 3D acquisition.

MR SPECTROSCOPY
===============

MRS provides insight into the metabolic profile of interrogated tissue. The most recognizable metabolites on ^1^H-MRS, which are of primary interest in the evaluation of brain tumors, include N-acetylaspartate (NAA) at approximately 2.0 parts per million (ppm), creatine (Cr) at approximately 3.0 ppm, and choline (Cho) at approximately 3.2 ppm \[[@B131]\]. NAA is considered a neuronal marker, Cr a marker for cellular metabolism, and Cho a marker for cell membrane turnover. Additional metabolites of interest include lipid and lactate peaks at approximately 1.3 ppm and myo-inositol at approximately 3.5 ppm. Lipids and lactate are considered markers of necrosis and hypoxia, respectively, and myo-inositol is considered to be related to astrocytic integrity and regulation of brain osmosis \[[@B131],[@B132],[@B133],[@B134]\].

The MRS profile of gliomas is generally considered elevated Cho and decreased NAA \[[@B135],[@B136],[@B137]\]. Cho is not a marker of tumor but reflects increase in cell membrane turnover and NAA represents a neuronal marker. Absolute heights of the MRS peaks are generally not used and the metabolic peaks are generally analyzed as ratios including Cho-NAA and Cho-Cr ([Fig. 3](#F3){ref-type="fig"}). MRS can potentially be used to differentiate high-grade gliomas from low-grade gliomas as high-grade gliomas have been found to have higher Cho-NAA and Cho-Cr ratios than lower-grade gliomas \[[@B137],[@B138]\]. Furthermore, an elevated myo-inositol/Cr ratio (myo-inositol is best identified with a short echo time of 35 ms) is associated with lower-grade gliomas \[[@B132]\]. Elevated Cho-NAA and Cho-Cr ratios in the peritumoral T2/FLAIR adjacent to an enhancing lesion can also be used to distinguish the peritumoral infiltrative edema of high-grade gliomas, which has elevated Cho-NAA and Cho-Cr ratios reflecting the cellular nature of the signal abnormality, from the peritumoral vasogenic edema surrounding metastases \[[@B80],[@B139]\]. MRS may also useful in the ongoing evaluation of patients with known brain tumors. In the situation of possible pseudo-progression or radiation necrosis, elevated Cho-NAA or Cho-Cr have been reported to be suggestive of tumor while non-elevated ratios are suggestive of pseudo-progression or radiation necrosis, however, in practice this may be a challenging distinction to make on MRS \[[@B140],[@B141],[@B142],[@B143],[@B144]\].

The lipid and lactate peaks overlap on standard MRS and may be interpreted as one metabolite even through they provide different and unique information or potentially cancel each other\'s signal on lactate-edited MRS is a technique which can reliable separate the lactate doublet peak from lipid peaks \[[@B145]\]. Lactate-edited MRS is of interest as lactate reflecting hypoxia and anaerobic metabolism is encountered in high and low-grade gliomas whereas lipid, representing necrosis is seen in high-grade gliomas \[[@B146]\]. Higher levels of lactate and lipids in patients with glioblastoma have also been associated with worse overall survival \[[@B147]\].

A related emerging method currently confined to research use is hyperpolarized ^13^C MR. Hyperpolarized ^13^C agents have a dramatically increased signal, which provides the opportunity to follow a substance such as pyruvate through its biochemical pathways as it is converted to alanine, lactate, and bicarbonate \[[@B148],[@B149]\]. In animal brain tumor models hyperpo-larized ^13^C labeled lactate has been demonstrated within tu-mors with a reduction in lactate following treatment with te-mozolamide \[[@B150]\]. Hyperpolarized ^13^C MRS has also been shown to be able to detect *IDH1* mutation status by analyzing the metabolites of hyperpolarized ^13^C alpha ketoglutarate in an animal tumor model \[[@B151]\].

FUNCTIONAL MRI
==============

Functional MRI (fMRI) utilizes relative changes in the blood oxygen level dependent (BOLD) signal to infer brain activity \[[@B152]\]. fMRI can be either task-based where the sequence is performed during the performance of a task or during exposure to a stimulus, or non-task based where the sequence is performed at rest and termed resting-state fMRI (RS-fMRI). RS-fMRI uses spontaneous low frequency fluctuations (\<0.1 Hz) in the BOLD signal to pick out areas of correlation and anti-correlation, which form the basis for defining resting-state networks, the most widely studied of which is the default mode network \[[@B152],[@B153],[@B154],[@B155]\]. Vascular tumors can potentially affect the BOLD signal, however, both task based and RS-fMRI have been effectively applied in patients with brain tumors.

Task based fMRI can be used for pre-operative localization of eloquent cortex with identification of language and somatomotor function with similar accuracy to more invasive techniques ([Fig. 5](#F5){ref-type="fig"}) \[[@B156],[@B157],[@B158]\]. Task based fMRI has thus been used for preoperative planning in order to identify the relationship of eloquent functional cortex to brain tumors \[[@B159]\]. The distance from the tumor to functional area depicted on task-based fMRI has been shown to be related to the degree of postoperative loss of function with a small margin (\<1 cm) predicting a poorer neurologic outcome \[[@B159]\].

RS-fMRI has also been used to identify eloquent cortex as part of pre-surgical planning in brain tumor patients although the experience is more limited \[[@B160]\]. RS-fMRI carries some distinct advantages over task based fMRI including not having to administer a paradigm, the ability to study patients who may not be able cooperate with a paradigm (children, patients with altered mental status, etc.), and the ability to detect many networks retrospectively from one sequence. Although the experience is more limited, several studies have demonstrated the ability to localize somatosensory cortex in relationship to brain tumors \[[@B161],[@B162]\]. RS-fMRI offers the ability to study functional connectivity of the brain and is thus a potentially powerful sequence for studying the healthy and diseased brain. RS-fMRI may potentially be used in the future to study not only the effects of brain tumors on the brain, but also the effects of treatment. To date there have been several small studies which have demonstrated decreased functional connectivity in resting state networks in brain tumor patients but this will likely be an area of active research in the future \[[@B163],[@B164],[@B165]\].

PET MRI
=======

Integrated PET/MRI systems offers the ability to perform state of the art structural MR imaging simultaneously with physiologic PET imaging and is an area of active research \[[@B166],[@B167]\]. The ideal radiotracer has robust uptake in the targeted lesion with minimal physiological uptake in normal background tissues. The high glucose metabolic activity of the brain and gliomas limits the utility of ^18^F-fluorodeoxyglucose PET imaging due to the poor tumor to background contrast \[[@B168],[@B169]\].

New PET tracers however may offer additional insight into brain tumor physiology. The amino acid PET tracers ^11^C-methionine (MET) and ^18^F-flouroethyltyrosine (FET) demonstrate increased uptake in gliomas as compared to normal brain and elevated uptake in high-grade gliomas as compared to low-grade gliomas \[[@B170],[@B171],[@B172],[@B173]\]. Furthermore these agents may offer prognostic information as poorer survival has been associated in low-grade glioma patients with elevated MET \[[@B170]\]. These amino acid PET tracers may also be useful for distinguishing recurrent/progressive tumor from pseudo-progression/treatment effect with both relative elevated MET and FET suggesting tumor \[[@B174],[@B175]\]. However, the clinical utility of MET is limited by it\'s short half-life of 20.3 minutes and need for an onsite cyclotron. ^18^F-flouro-L-dopa (FDOPA) is additional marker of amino acid synthesis. FDOPA uptake has been shown to correlate with regions of high proliferation and demonstrate uptake in low and high-grade gliomas \[[@B176],[@B177]\]. FDOPA has also been reported to be elevated in recurrent/progressive tumor as compared to radiation necrosis \[[@B176],[@B178]\].

^18^F-flouromisoidazole (FMISO) PET is a non-invasive method that can physiologically estimate tissue hypoxia ([Fig. 6](#F6){ref-type="fig"}) \[[@B179],[@B180],[@B181],[@B182],[@B183]\]. Several studies have validated FMISO uptake as a robust measure of tissue hypoxia, and established methodology for FMISO PET imaging \[[@B179],[@B180],[@B181],[@B182],[@B183]\]. A preliminary study of 22 participants with glioblastoma demonstrated an association with both the pre-radiation volume and degree of tumor hypoxia measured by FMISO PET and a shorter time to tumor progression and survival \[[@B183]\]. Consequently, knowledge of the amount and distribution of tumor hypoxia may provide prognostic information as well as useful information to guide therapy for patients with glioblastoma. The use of hypoxia imaging markers could serve as early biomarkers of radiation resistant areas and provide insight into patient prognosis prior to anti-angiogenic therapy.

CONCLUSION
==========

The imaging and clinical management of patients with brain tumor continue to evolve over time and now heavily relies on physiologic imaging in addition to high-resolution structural imaging. As our understanding of the biology of brain tumors and our imaging abilities increase there is a great opportunity to positively impact the care of brain tumor patients. Ongoing research is required to understand the interactions of our modern neuroimaging techniques with advancements in tumor genetics, therapeutics, and neuroscience. Many of the established and developing imaging techniques discussed in this review may offer additional insight into genetic, prognostic, and predictive information that may be further elucidated in the future. The current state of brain tumor imaging contributes greatly to improving preoperative diagnosis, predicting tumor grading and patient prognosis, planning surgery and radiation therapy, and assessing treatment response. Imaging remains a powerful noninvasive tool to positively impact the management of patients with brain tumor.
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![57-year-old male patient who presented with loss of consciousness and seizure and who initially had a non-contrast CT (A) performed that demonstrated a partially calcified mass in the left frontal lobe. Preoperative MR images include axial T2 FLAIR (B), axial T1 post-contrast (C), axial SWI (D), coronal T2 FLAIR (E), axial DWI (F), axial ADC map (G), and DTI tractography of the left corticospinal tract superimposed on axial T2 (H). This T2/FLAIR hyperintense (B, E, and H), non-enhancing mass (C), with internal calcifications visible on CT (A) and as susceptibility on SWI (D) was a grade II oligoastrocytoma (*TP53* mutation negative, *IDH1* mutation positive, 1p19q co-deletion positive). A gross total resection was performed and the patient remains alive. ADC, apparent diffusion coefficient; CT, computed tomography; DTI, diffusion-tensor imaging; DWI, diffusion weighted imaging; FLAIR, fluid attenuated inversion recovery; MR, magnetic resonance; SWI, susceptibility weighted imaging.](btrt-3-8-g001){#F1}

![78-year-old female patient with a glioblastoma who presented with gait instability, dizziness, and dysarthria for 6-8 weeks. Preoperative MR images include axial T1 post-contrast (A), coronal T1 post-contrast (B), axial T2 FLAIR (C), axial DWI (D), axial ADC map (E), axial DSC perfusion (F), and corresponding perfusion curve (G). Post-contrast T1 images (A and B) demonstrate irregular rim enhancement and central necrosis of this tumor centered in the right frontal lobe. Surrounding the enhancing component is T2 FLAIR hyperintensity (C) which is likely infiltrative cellular edema. The lesion demonstrates restricted diffusion with low ADC values (D and E) and increased relative cerebral blood volume compared to the contralateral side (F and G) with return to baseline of the perfusion curve consistent with a primary glial tumor. ADC, apparent diffusion coefficient; DSC, dynamic susceptibility contrast-enhanced; DWI, diffusion weighted imaging; FLAIR, fluid attenuated inversion recovery; MRI, magnetic resonance image.](btrt-3-8-g002){#F2}

![33-year-old female patient with a left insular glioblastoma (19q deletion, 1p intact, *IDH1* mutation, *PTEN* and *EGFR* mutation negative) who presented with syncope and seizure. Preoperative MR images include axial T1 post-contrast (A), axial T2 FLAIR (B), axial DWI (C), axial ADC map (D), spectroscopy with choline to NAA ratio overlay on axial T1 post-contrast (E), corresponding spectroscopy and choline to NAA ratios (F), axial DSC perfusion (G), corresponding perfusion curve (H), and DTI tractography of the left corticospinal tract (I) and left arcuate fasciculus (J) superimposed on axial T2. Post-contrast T1 image (A) demonstrate irregular patchy partial enhancement within the tumor. T2 FLAIR (B) shows the extent of non-enhancing T2 FLAIR hyperintense tumor. The lesion demonstrates areas of restricted diffusion with low ADC values (C and D) and increased relative cerebral blood volume compared to the contralateral side (G and H) with return to baseline of the perfusion curve consistent with a primary glial tumor. Spectroscopy (E and F) demonstrates elevated choline relative to NAA, consistent with a glioma. ADC, apparent diffusion coefficient; DSC, dynamic susceptibility contrast-enhanced; DTI, diffusion tensor imaging; DWI, diffusion weighted imaging; *EGFR*, epidermal growth factor receptor; FLAIR, fluid attenuated inversion recovery; *IDH*, isocitrate dehydrogenase; MRI, magnetic resonance image; NAA, N-acetylaspartate; *PTEN*, phosphatase and tensin homolog.](btrt-3-8-g003){#F3}

![49-year-old female patient with two months of headaches and falls and a remote history of right lung lobectomy for reported benign tumor with MR imaging demonstrating a solitary mass in the right cingulate gyrus which upon resection was metastatic adenocarcinoma (ultimately metastatic non-small cell lung cancer). Preoperative MR images include axial T1 post-contrast (A), axial T2 FLAIR (B), axial DSC perfusion (C), and corresponding perfusion curve (D). Post-contrast T1 image (A) demonstrates the solitary enhancing mass. T2 FLAIR (B) shows the large amount of peri-tumoral vasogenic edema. DSC perfusion (C and D) shows elevated cerebral blood volume relative to the contralateral side without return of the curve to baseline, suggesting a solitary metastasis as opposed to a glioma. DSC, dynamic susceptibility contrast-enhanced; FLAIR, fluid attenuated inversion recovery; MRI, magnetic resonance image.](btrt-3-8-g004){#F4}

![64-year-old male patient who presented with expressive aphasia and dysarthria and ultimately was diagnosed with glioblastoma (*IDH1* non-mutated, *PTEN* deleted, *EGFR* amplification negative) and underwent a subtotal resection. Preoperative MR images include axial T1 post-contrast (A) demonstrating a peripherally enhancing mass, and task based BOLD-fMRI functional maps superimposed on anatomic images (B-F) (courtesy of Pratik Mukherjee, MD, PhD). A tongue movement paradigm (B and C) demonstrated bilateral supra-sylvian peri-rolandic activation, which on the left abuts the posterior aspect of the tumor anteriorly as demonstrated on axial (B) and sagittal (C) images. A covert visual verb generation paradigm localized expressive language function to the left (D and E), which was anterior to the tumor but approached the anterior inferior aspect of the tumor (not pictured). A passive listening paradigm localized receptive language function to the left (F), separate from the tumor. *EGFR*, epidermal growth factor receptor; fMRI, functional magnetic resonance image; *IDH*, isocitrate dehydrogenase; MRI, magnetic resonance image; *PTEN*, phosphatase and tensin homolog.](btrt-3-8-g005){#F5}

![Single modality FMISO PET/MR imaging in a 65-year-old man with recurrent left temporal lobe WHO grade III anaplastic astrocytoma. Simultaneously obtained, axial FMISO PET (A), post contrast T1-weighted (B), and fused T1 post contrast FMISO (C) PET/MR demonstrates recurrence of disease evidenced by contrast enhancing focus bordering the posterior margin of an anterior left temporal lobe resection cavity. This region demonstrates increased FMISO uptake. FMISO, ^18^F-flouromisoidazole; MR, magnetic resonance; PET, positron emission tomography; WHO, World Health Organization.](btrt-3-8-g006){#F6}

###### Genetic mutations in brain tumors with current clinical and imaging implications
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  Genetic mutations and clinical imaging implications/associations                                                                                 
  ------------------------------------------------------------------ ----------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  *IDH1/2* mutations                                                 Oligodendroglial tumors                                                       Minimal or no contrast enhancement
  Positive prognostic factor                                         Reported detection of 2-HG by MRS                                             
  Research into hyperpolarized C13 detection in animal models                                                                                      
  1p19q deletion                                                     Oligodendroglial tumors                                                       Reported more heterogeneous signal characteristics
  Reported elevated perfusion                                                                                                                      
  *MGMT* promoter methylation                                        Pseudo-progression more common                                                Pseudo-progression more common
  Alkylating agents                                                                                                                                
  *ATRX* deletion                                                    Astrocytic tumors                                                             
  Not seen with 1p19q deletion                                                                                                                     
  *PTEN* deletion                                                    Small cell phenotype of glioblastoma with *EGFR* amplification and 10q loss   Reported increased perfusion in tumors with *PTEN* mutation, *EGFR* amplification, unmethylated *MGMT* promoter
  *EGFR* amplification                                               Reported in approximately 40% of glioblastomas                                Reported increased perfusion
  Reported lower ADC values, higher enhancing/necrotic volume                                                                                      

ADC, apparent diffusion coefficient; *ATRX*, alpha thalassemia-mental retardation syndrome X-linked; C-13, carbon 13; *EGFR*, epidermal growth factor receptor; *IDH*, isocitrate dehydrogenase; *MGMT*, O^6^-methylguanine-DNA methyl-transferase; MRS, magnetic resonance spectroscopy; PTEN, phosphatase and tensin homolog; 2-HG, 2-hydroxyglutarate

###### Imaging methods and the major utility in brain tumor imaging
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  Imaging technique                      Major utility in brain tumor imaging
  -------------------------------------- -------------------------------------------------------------------------------------
  CT                                     Mass effect, herniation, hydrocephalus, hemorrhage, calcifications
  Pre and post-contrast T1               Enhancement characteristics, necrosis, extent of the enhancing portion of the tumor
  T2/T2 FLAIR                            Peri-tumoral edema (vasogenic and infiltrative), non-enhancing tumor
  T2^\*^ susceptibility sequence (SWI)   Blood products, calcifications, radiation induced chronic micro-hemorrhages
  DWI/ADC                                Reduced in highly cellular portions of tumor, post-operative injury
  DTI                                    Tractography for surgical planning/navigation
  Perfusion (generally DSC)              Tumor/tissue vascularity
  MR spectroscopy                        Metabolic profile
  fMRI                                   Pre-operative functional mapping, research into treatment effects
  PET/MR                                 Potential new radiotracers

ADC, apparent diffusion coefficient; CT, computed tomography; DSC, dynamic susceptibility contrast-enhanced; DTI, diffusion tensor imaging; DWI, diffusion weighted imaging; FLAIR, fluid attenuated inversion recovery; fMRI, functional magnetic resonance imaging; PET, positron emission tomography; SWI, susceptibility weighted imaging
